Earnings
Kymera CEO Says Oral Eczema Pill Can Win Without Matching Biologics, Yet Expects Dupixent-Like Results
Nello Mainolfi says 400,000 of 6 million to 9 million US patients get advanced therapies, with KT621 Phase 2b data due by year-end.
KYMR
Kymera Therapeutics (KYMR) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Kymera CEO Says 'We Probably Taught The Market Too Much' With KT621, So KT579 Details Stay Private
Kymera is holding back dose-response data on its lupus drug KT579 while reporting more than 90% IRF5 degradation in its top five dose cohorts.
Earnings
Kymera Sold $219.9 Million Of Stock Through Its At-The-Market Program, Then Subleased Its Old Lab To A Director's Other Company
The biotech's third-quarter 10-Q shows 2,032,140 shares sold at the market and a related-party sublease of its former Watertown lab.
Earnings
Kymera's KT-579 Degrades At Least 90% Of IRF5 In Blood, With Placebo-Like Safety In Healthy Volunteers
The company plans a lupus trial by early 2027 and says its $1.6 billion in cash lasts into 2029, as its third-quarter loss widened.